Reference Interval:
| Components
| Reference Interval
| | Purkinje Cell Cytoplasmic Ab (PCCA or PCA-1) Screen
| Less than 1:10
| | Purkinje Cell Cytoplasmic Ab (PCCA or PCA-1) Titer
| < 1:10
| | Purkinje Cell Cytoplasmic Ab (PCCA or PCA-1) Immunoblot
| Negative
|
|
| Interpretive Data: |
There is a strong association among paraneoplastic syndromes, anti-neuronal antibody specifications and the associated tumor type. However, in a minority of patients with paraneoplastic syndrome with anti-neuronal antibodies, no tumor may be found. Certain patients with paraneoplastic syndromes may not have detectable levels (by IFA) of anti-neuronal antibodies. Most cases that develop PCD in association with Hodgkin's disease, non-SCLC, gastrointestinal carcinomas do not have demonstrable anti-Yo antibodies. There also exist anti-Yo negative but atypical anti-Purkinje cell cytoplasm autoantibodies (atypical APCA's). Such antibodies can occur in association with Hodgkin's disease, adenocarcinoma of the lung, colon, or prostate. 5-6% patients with ovarian cancer have circulating anti-Yo or anti-Ri antibodies in the absence of any paraneoplastic neurological syndromes.
Please refer to Statement D in the Compliance Statements section in the front of the Laboratory Test Directory.
|
| Note: |
If Purkinje cell screen is 1:10, then a titer and immunoblot will be added.
|
| CPT Code(s): |
86255; if reflexed, add 86256 Titer; 83516 Immunoblot
|
|